Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Iovance Biotherapeutics, Inc. (IOVA)'s share was trading at $2.3500 as of January 13th. Photographee.eu/Shutterstock.com Iovance Biotherapeutics is pursuing a high-risk Believer Strategy, opting to fund operations through ongoing equity dilution rather than selling the company at a distressed valuation near $2.50 per share. Management and influential insiders remain deeply confident in the long term potential of the Tumor Infiltrating Lymphocyte platform, particularly in lung cancer, which they believe can ultimately support a multibillion-dollar opportunity. This conviction has driven a willingness to sell stock to maintain operations instead of accepting a takeout at current prices. As a result, the stock trades like a failed biotech while control rests with high conviction insiders such as Wayne Rothbaum, whose estimated cost basis is closer to $9.00, creating a sharp disconnect between market perception and internal expectations. This valuation gap has effectively frozen s
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)GlobeNewswire
- Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 11/6/25 - Beat
IOVA
Sec Filings
- 1/9/26 - Form 8-K
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IOVA's page on the SEC website